Article Data

  • Views 392
  • Dowloads 147

Original Research

Open Access

A radiomics model derived by combination of radiomics signature and clinical risk factors predict of lymph node metastasis for men renal pelvis urothelial carcinoma

  • Jingyi Huang1
  • Fan Chen1
  • Chengcheng Gao2
  • Zhenyu Shu3
  • Gang Tao4,*,

1Department of Radiology, Zhejiang Medical and Health Group Hangzhou Hospital, 310022 Hangzhou, Zhejiang, China

2Department of Radiology, Hangzhou First People’s Hospital, 310006 Hangzhou, Zhejiang, China

3Department of Radiology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, 314408 Hangzhou, Zhejiang, China

4Department of Oncology, Zhejiang Medical and Health Group Hangzhou Hospital, 310022 Hangzhou, Zhejiang, China

DOI: 10.22514/jomh.2024.072 Vol.20,Issue 5,May 2024 pp.68-75

Submitted: 21 October 2023 Accepted: 21 November 2023

Published: 30 May 2024

*Corresponding Author(s): Gang Tao E-mail:


This study aims to propose a radiomics model to identify male patients suffering from renal pelvis urothelial carcinoma (RPUC) with preoperative lymph node (LN) metastasis. In a study involving 133 male RPUC patients, 94 were assigned to a training group and 39 to a testing group. Their arterial-phase computed tomography (CT) images were analyzed to extract radiomics features, which were then refined through data reduction and feature selection. Using the least absolute shrinkage and selection operator (LASSO), a radiomics signature was created, which was then incorporated into a Logistic regression classifier in the training group to predict pathologic lymph node metastases. A comprehensive radiomics model was developed using multivariate logistic regression, integrating clinical risk factors. The model’s efficacy was evaluated in both sets using discrimination, calibration and decision curve analyses in both the training and testing sets. The constructed signature, composed of eight promising imaging-derived features, showed strong discrimination ability in both sets (training: area under the curve (AUC) 0.836 and testing: AUC, 0.817). When combined with CT-reported tumor status, the radiomics model demonstrated excellent calibration and discrimination, achieving an AUC of 0.849 in the training set and 0.851 in the testing set. The radiomics model, incorporating both the radiomics signature and the CT-reported tumor status, could help in the preoperative individualized prediction of LN metastasis in male patients with RPUC.


Renal pelvis urothelial carcinoma; Radiomics; Lymph node metastasis; Computed tomography; Men

Cite and Share

Jingyi Huang,Fan Chen,Chengcheng Gao,Zhenyu Shu,Gang Tao. A radiomics model derived by combination of radiomics signature and clinical risk factors predict of lymph node metastasis for men renal pelvis urothelial carcinoma. Journal of Men's Health. 2024. 20(5);68-75.


[1] Soria F, Shariat SF, Lerner SP, Fritsche H, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology. 2017; 35: 379–387.

[2] Wu J, Chen S, Wu X, Mao W, Wang Y, Xu B, et al. Trends of incidence and prognosis of upper tract urothelial carcinoma. Bosnian Journal of Basic Medical Sciences. 2021; 21: 607–619.

[3] Xu C, Yuan C, Zhang C, Fang D, Yu Y, Wang X, et al. The evolution of clinicopathological diagnostic features of upper tract urothelial carcinoma in China: a summary of 2561 cases in the last 20 years. Frontiers in Oncology. 2022; 12: 769252.

[4] Califano G, Ouzaid I, Verze P, Hermieu J, Mirone V, Xylinas E. Immune checkpoint inhibition in upper tract urothelial carcinoma. World Journal of Urology. 2021; 39: 1357–1367.

[5] Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. European Urology. 2021; 79: 62–79.

[6] Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, et al. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. European Urology Oncology. 2020; 3: 73–79.

[7] Pallauf M, D’Andrea D, König F, Laukhtina E, Yanagisawa T, Rouprêt M, et al. Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients: a multicenter, retrospective, observational study. Journal of Urology. 2023; 209: 515–524.

[8] Rodler S, Solyanik O, Ingenerf M, Fabritius M, Schulz GB, Jokisch F, et al. Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer. World Journal of Urology. 2022; 40: 1707–1714.

[9] Dłubak A, Karwacki J, Logoń K, Tomecka P, Brawańska K, Krajewski W, et al. Lymph node dissection in upper tract urothelial carcinoma: current status and future perspectives. Current Oncology Reports. 2023; 25: 1327–1344.

[10] Richters A, van Ginkel N, Meijer RP, Wondergem M, Schoots I, Vis AN, et al. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle‐invasive bladder cancer: a nationwide population-based study. BJU International. 2023; 132: 420–427.

[11] Amudala Puchakayala PR, Sthanam VL, Nakhmani A, Chaudhary MFA, Kizhakke Puliyakote A, Reinhardt JM, et al. Radiomics for improved detection of chronic obstructive pulmonary disease in low-dose and standard-dose chest CT scans. Radiology. 2023; 307: e222998.

[12] Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology. 2023; 308: e222646.

[13] Shin J, Seo N, Baek S, Son N, Lim JS, Kim NK, et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy. Radiology. 2022; 303: 351–358.

[14] Carbonell G, Kennedy P, Bane O, Kirmani A, El Homsi M, Stocker D, et al. Precision of MRI radiomics features in the liver and hepatocellular carcinoma. European Radiology. 2022; 32: 2030–2040.

[15] Chetan MR, Gleeson FV. Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. European Radiology. 2021; 31: 1049–1058.

[16] Kobayashi S, Ito M, Takemura K, Suzuki H, Yonese I, Koga F. Preoperative models incorporating the systemic immune-inflammation index for predicting prognosis and muscle invasion in patients with non-metastatic upper tract urothelial carcinoma. International Journal of Clinical Oncology. 2022; 27: 574–584.

[17] Aydh A, Abufaraj M, Mori K, Quhal F, Pradere B, Motlagh RS, et al. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. Arab Journal of Urology. 2021; 19: 59–66.

[18] Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, et al. Postoperative nomogram to predict cancer‐specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU International. 2014; 114: 733–740.

[19] Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. European urology. 2012; 818–825.

[20] Sugino Y, Sasaki T, Kato M, Masui S, Nishikawa K, Okamoto T, et al. Prognostic effect of preoperative psoas muscle Hounsfield unit at radical cystectomy for bladder cancer. Cancers. 2021; 13: 5629.

[21] Miura N, Mori K, Laukhtina E, Schuettfort VM, Abufaraj M, Teoh JYC, et al. Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Japanese Journal of Clinical Oncology. 2021; 51: 1149–1157.

[22] Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, et al. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urologic Oncology. 2014; 32: 48.e19–48.e26.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time